Acquisition Opportunity Courante Oncology was acquired by Harvest Integrated Research Organization (HiRO) in August 2023, indicating a shift in ownership and potential integration needs. This presents a sales opening to align HiRO’s CRO capabilities with Courante’s oncology-focused trial management to optimize post-merger research efficiency.

Boutique CRO Upsell As a small-scale oncology CRO with 2-10 employees, Courante may benefit from scalable project management, monitoring, and quality assurance services to handle larger trial portfolios or peak workloads without compromising quality.

Strategic Partnership HiRO’s global footprint combined with Courante’s oncology specialization suggests an opportunity to offer joint service packages that leverage global trial operations, site monitoring, and medical writing support for multinational oncology programs.

Tech Modernization Current tech stack includes Snowplow, Mustache, Video.js and other tools; there is potential to upsell modern analytics, digital trial platforms, and integrated eConsent or data capture solutions to improve trial efficiency and data quality.

Revenue Growth Reported revenue range of one to ten million dollars signals room for contract expansions, bundled services, and longer-term engagement opportunities with HiRO to drive revenue growth through expanded scope and repeat engagements.